Kidney injuries related to ipilimumab

Investigational New Drugs

Volumn 32, Issue 4, 2014, Pages 769-773

  Izzedine, Hassane ^a   Gueutin, Victor ^a   Gharbi, Chems ^a   Mateus, Christine ^b   Robert, Caroline ^b   Routier, Emilie ^b   Thomas, Marina ^b   Baumelou, Alain ^a   Rouvier, Philippe ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Acute kidney injury; CTLA 4 inhibitors; Granulomatous interstitial nephritis; Melanoma

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MONOCLONAL ANTIBODY;

AGED; ANTAGONISTS AND INHIBITORS; CASE REPORT; CHEMICALLY INDUCED; FEMALE; HUMAN; KIDNEY DISEASE; MALE; MIDDLE AGED;

AGED; ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED;

EID: 84904553412     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0092-7     Document Type: Article

References (22)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
2. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci 100:4712-4717 (Pubitemid 36457795)
3. Friedline RH, Brown DS, Nguyen H, Kornfeld H, Lee J, Zhang Y, Appleby M, Der SD, Kang J, Chambers CA (2009) CD4+ Regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 206:421-434
4. Chmiel KD, Suan D, Liddle C, Nankivell B, Ibrahim R, Bautista C, Thompson J, Fulcher D, Kefford R (2011) Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 29:e237-e240
5. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Heinzerling LM (2013) The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 8:e537-545
6. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24:2283-2289 (Pubitemid 46630658)
7. Fadel F, El Karoui K, Knebelmann B (2009) Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361:211-212
8. Forde PM, Rock K, Wilson G, O'Byrne KJ (2012) Ipilimumab-induced immune-related renal failure - a case report. Anticancer Res 32:4607-4608
9. Lebbe C, O'Day S, Chiarion Sileni V, Gajewski T, Pehamberger H, Bondarenko I, Queirolo P, Lundgren S, Roman L, Verschraegen C, Ibrahim R, Chin K, Hoos A, Maio M (2008). Analysis of the onset and resolution of immune related adverse events during treatment with ipilimumab in patients with metastatic melanoma. (oral abstract O-015, Perspectives in Melanoma XII).
10. Haas M, Spargo BH, Wit EJ, Meehan SM (2000) Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis 35:433-447
11. Spanou Z, Keller M, Britschgi M, Yawalkar N, Fehr T, Neuweiler J, Gugger M, Mohaupt M, Pichler WJ (2006) Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol 17:2919-2927 (Pubitemid 44484683)
12. Clarkson MR, Giblin L, O'Connell FP, O'Kelly P, Walshe JJ, Conlon P, O'Meara Y, Dormon A, Campbell E, Donohoe J (2004) Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant 19:2778-2783 (Pubitemid 39480972)
13. Bhaumik SK, Kher V, Arora P, Rai PK, Singhal M, Gupta A, Pandey R, Sharma RK (1996) Evaluation of clinical and histological prognostic markers in drug-induced acute interstitial nephritis. Ren Fail 18:97-104
14. Schwarz A, Krause PH, Kunzendorf U, Keller F, Distler A (2000) The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol 54:179-190
15. Harmankaya K, Erasim C, Koelblinger C, Ibrahim R, Hoos A, Pehamberger H, Binder M (2011) Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol 28:1140-1144
16. Lute KD, May KF Jr, Lu P, Zhang H, Kocak E, Mosinger B, Wolford C, Phillips G, Caligiuri MA, Zheng P, Liu Y (2005) Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood 106:3127-3133 (Pubitemid 41565910)
17. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27:68-73 (Pubitemid 32044521)
18. Bennett CL, Ochs HD (2001) IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr Opin Pediatr 13:533-538 (Pubitemid 34015524)
19. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27:20-21 (Pubitemid 32044513)
20. Liu SM, Sutherland AP, Zhang Z, Rainbow DB, Quintana FJ, Paterson AM, Sharpe AH, Oukka M, Wicker LS, Kuchroo VK (2012) Overexpression of the Ctla-4 isoform lacking exons 2 and 3 causes autoimmunity. J Immunol 188:155-162
21. Wang HB, Shi FD, Li H, Chambers BJ, Link H, Ljunggren HG (2001) Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 166:6430-6436 (Pubitemid 32440778)
22. Matsui T, Kurokawa M, Kobata T, Oki S, Azuma M, Tohma S, Inoue T, Yamamoto K, Nishioka K, Kato T (1999) Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J Immunol 162:4328-4335 (Pubitemid 29314825)